Patent application number | Description | Published |
20110275679 | FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL - The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal. | 11-10-2011 |
20110275681 | NOVEL SOLID FORMS OF EPALRESTAT - The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic. | 11-10-2011 |
20110275682 | NOVEL CHOLINE COCRYSTAL OF EPALRESTAT - The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients. | 11-10-2011 |
20110281911 | NOVEL FORMS OF EPERISONE - The invention relates to substantially enantiopure crystalline salt forms of (2RS)-I-(4-Ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one. The preparation and characterization of the substantially enantiopure crystalline salt forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the substantially enantiopure crystalline salt forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotome conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension. | 11-17-2011 |
20120076857 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 03-29-2012 |
20120196895 | NOVEL FORMS OF EPERISONE - The invention relates to novel crystalline forms of (2RS)-1-(4-ethylphenyl)-2-methyl-3-piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotonic conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension. | 08-02-2012 |
20130066079 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 03-14-2013 |
20140221438 | NOVEL SOLID FORMS OF EPALRESTAT - The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic. | 08-07-2014 |
20150057319 | NOVEL CHOLINE COCRYSTAL OF EPALRESTAT - The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients. | 02-26-2015 |
Patent application number | Description | Published |
20100174064 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them. | 07-08-2010 |
20100239664 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 09-23-2010 |
20120316334 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them. | 12-13-2012 |
20140141081 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 05-22-2014 |
20140179916 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them. | 06-26-2014 |
Patent application number | Description | Published |
20120046442 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 02-23-2012 |
20140256637 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 09-11-2014 |
20140336132 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 11-13-2014 |
20150218225 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 08-06-2015 |
Patent application number | Description | Published |
20090030213 | Stabalized Vegetable Oils And Methods Of Making Same - A method for modifying ethylenic unsaturation in a triglyceride. One or more unsaturated fatty acyl moieties present in the triglyceride are substituted with a lactone or ketone moiety via a electron donor mediated reaction. The resulting reaction products are useful, for example, as formulations for lubricants, hydraulic fluids, dielectric fluids, and intermediates for polymer synthesis. | 01-29-2009 |
20090205535 | Stabilized Vegetable Oils And Methods Of Making Same - A method for modifying ethylenic unsaturation in a triglyceride. One or more unsaturated fatty acyl moieties present in the triglyceride are substituted with a a lactone substitution, a dihydrofuran substitution, or a ketone substitution via an electron acceptor mediated reaction. The resulting reaction products are useful, for example, as lubricants, metalworking fluids, mold release agents, hydraulic fluids, or dielectric fluids, or as components of lubricants, metalworking fluids, mold release agents, hydraulic fluids, or dielectric fluids, and modified fatty acids for polymer synthesis. | 08-20-2009 |
Patent application number | Description | Published |
20090057550 | SYSTEMS AND METHODS FOR DISCOVERY AND ANALYSIS OF MARKERS - A business method for use in classifying patient samples. The method includes steps of collecting case samples representing a clinical phenotypic state and control samples representing patients without said clinical phenotypic state. Preferably the system uses a mass spectrometry platform system to identify patterns of polypeptides in said case samples and in the control samples without regard to the specific identity of at least some of said polypeptides. Based on identified representative patterns of the state, the business method provides for the marketing of diagnostic products using representative patterns. | 03-05-2009 |
20110315552 | Systems and Methods for Discovery and Analysis of Markers - A business method for use in classifying patient samples. The method includes steps of collecting case samples representing a clinical phenotypic state and control samples representing patients without said clinical phenotypic state. Preferably the system uses a mass spectrometry platform system to identify patterns of polypeptides in said case samples and in the control samples without regard to the specific identity of at least some of said polypeptides. Based on identified representative patterns of the state, the business method provides for the marketing of diagnostic products using representative patterns. The present invention relates to systems and methods for identifying new markers, diagnosing patients with a biological state of interest, and marketing/commercializing such diagnostics. The present invention relates to systems and methods of greater sensitivity, specificity, and/or cost effectiveness. | 12-29-2011 |
20140374584 | SYSTEMS AND METHODS FOR DISCOVERY AND ANALYSIS OF MARKERS - A business method for use in classifying patient samples. The method includes steps of collecting case samples representing a clinical phenotypic state and control samples representing patients without said clinical phenotypic state. Preferably the system uses a mass spectrometry platform system to identify patterns of polypeptides in said case samples and in the control samples without regard to the specific identity of at least some of said polypeptides. Based on identified representative patterns of the state, the business method provides for the marketing of diagnostic products using representative patterns. The present invention relates to systems and methods for identifying new markers, diagnosing patients with a biological state of interest, and marketing/commercializing such diagnostics. The present invention relates to systems and methods of greater sensitivity, specificity, and/or cost effectiveness. | 12-25-2014 |
Patent application number | Description | Published |
20100290759 | METHOD AND APPARATUS TO FACILITATE THE EFFICIENT IMPLEMENTATION OF TRICK MODES IN A PERSONAL VIDEO RECORDING SYSTEM - A method and apparatus are disclosed for facilitating efficient operation of trick modes in a personal video recording (PVR) system. Stream-navigation data from a data stream is captured and pre-processed to generate a frame-correlated NAV table comprising one entry for each frame within the data stream, during recording of the data stream. The stream-navigation data comprises start code data, content rating data, and conditional access data that is embedded in the data stream. During playback of the data stream in a user-selected trick mode, the frame-correlated NAV table is used to generate command packets that are sent to a data decoder along with selected frames of the data stream. The selected frames are decoded based on information in the command packets and certain selected frames may be displayed as part of the trick mode. | 11-18-2010 |
20130290637 | PER PROCESSOR BUS ACCESS CONTROL IN A MULTI-PROCESSOR CPU - A technique to provide hardware protection for bus accesses for a processor in a multiple processor environment where at least two zones are established to separate or segregate processor functionality. In one implementation, control registers within a cache memory that supports the multiple processors are loaded with addresses associated with access rights for a particular processor. Then, when an access request is generated, the registers are checked to authorize the access. | 10-31-2013 |
20140115580 | Set Top Box Application in a Concurrent Dual Environment - A set top box or like device utilizing virtualization techniques to isolate secure device resources from an untrusted software framework incorporated in the device. In one implementation, a first virtual machine container is provided for secure execution of a traditional set top box application, while a second virtual machine container is utilized to host a software framework or untrusted portions of a software framework. A secure access client/server interface is provided to support interactions between the first and second virtual machine containers. The software framework may comprise, for example, an Android framework supported by an underlying Linux operating system environment and isolated in a Linux resource container. Virtual container constructs in various embodiments may employ varying levels of hardware sandboxing, including use of dedicated processing resources in multi-processor environments. In further embodiments, the software framework may be partitioned into trusted and untrusted portions that are executed in separate virtual containers. | 04-24-2014 |
Patent application number | Description | Published |
20080263455 | GRAPHICAL USER INTERFACE FOR ELECTRONIC FILE SHARING - A method, implementable in a system coupled to a display device and a network, includes generating in a first region of a screen of the display device a user-interface portion associated with a first electronic destination address. The user-interface portion is configured to receive from a second region of the screen, in response to a command by a user of the system, a first icon representing a data set. In response to the user-interface portion receiving the first icon, a copy of the data set, or the data set itself, is electronically transferred over the network to the first destination address. | 10-23-2008 |
20080263456 | GRAPHICAL USER INTERFACE FOR ELECTRONIC FILE SHARING - A method, implementable in a system coupled to a display device and a network, includes generating on a screen of the display device a first icon representing a data set. In response to a command by a user of the system to transfer respective copies of the data set over the network to multiple recipients, a visual indication of the status of the transfer of the copies to the recipients is displayed in association with the first icon. In response to each copy being completely received by each recipient, the visual indication is prompted to indicate transfer completion. | 10-23-2008 |
20130145277 | GRAPHICAL USER INTERFACE FOR ELECTRONIC FILE SHARING - A method, implementable in a system coupled to a display device and a network, includes generating in a first region of a screen of the display device a user-interface portion associated with a first electronic destination address. The user-interface portion is configured to receive from a second region of the screen, in response to a command by a user of the system, a first icon representing a data set. In response to the user-interface portion receiving the first icon, a copy of the data set, or the data set itself, is electronically transferred over the network to the first destination address. | 06-06-2013 |
Patent application number | Description | Published |
20100152072 | Lubricating oil compositions - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having greater than 400 ppm of boron, based upon the total mass of the composition; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having at least about 1100 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of less than or equal to about 4:1. | 06-17-2010 |
20100152073 | Lubricating oil compositions - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having no more than about 600 ppm of boron, based upon the total mass of the composition; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having no more than about 800 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of about 5:1 to about 500:1. | 06-17-2010 |
20100152074 | Lubricating oil compositions - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having no more than about 400 ppm of boron; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having at least about 1100 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of less than or equal to about 4:1. | 06-17-2010 |
20120145114 | LUBRICATING OIL COMPOSITION - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having no more than about 400 ppm of boron; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having, at least about 1100 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of less than or equal to about 4:1. | 06-14-2012 |
20120145115 | LUBRICATING OIL COMPOSITION - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having no more than about 600 ppm of boron, based upon the total mass of the composition; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having no more than about 800 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of about 5:1 to about 500:1. | 06-14-2012 |
20120145116 | LUBRICATING OIL COMPOSITION - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having greater than 400 ppm of boron, based upon the total mass of the composition; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having at least about 1100 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of less than or equal to about 4:1. | 06-14-2012 |
20140100146 | LUBRICATING OIL COMPOSITION - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having no more than about 400 ppm of boron; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having at least about 1100 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of less than or equal to about 4:1. | 04-10-2014 |
20140106998 | LUBRICATING OIL COMPOSITONS - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having greater than 400 ppm of boron, based upon the total mass of the composition; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having at least about 1100 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of less than or equal to about 4:1. | 04-17-2014 |
20140106999 | LUBRICATING OIL COMPOSITIONS - A lubricating oil composition having a sulfur content of up to about 0.4 wt. % and a sulfated ash content of up to about 0.5 wt. % as determined by ASTM D874 is disclosed which comprises (a) a major amount of an oil of lubricating viscosity; (b) at least one oil-soluble or dispersed oil-stable boron-containing compound having no more than about 600 ppm of boron, based upon the total mass of the composition; and (c) at least one oil-soluble or dispersed oil-stable molybdenum-containing compound having no more than about 800 ppm of molybdenum, based upon the total mass of the composition; wherein the lubricating oil composition has a ratio of sulfur to molybdenum of about 5:1 to about 500:1. | 04-17-2014 |